BMS’s Mezigdomide Myeloma Data Give Glimpse Of CELMoD Future
Phase I/II Results Published In NEJM
The trial’s principal investigator said the goal is to establish mezigdomide for use in patients who have failed on Pomalyst. BMS is running a head-to-head trial of both drugs.
